

SPECIAL TOPIX

Biosimilars Today and Tomorrow

Service Overview

The **Special Topix™: Biosimilars Today and Tomorrow (US)** service includes access to six reports across dermatology, gastroenterology, rheumatology, ophthalmology, neurology, and nephrology and will be available on a specialty basis. The reports will help manufacturers with biosimilar agents in the pipeline understand the current landscape and overall biosimilar class perspective, as well as provide insight for competitors on initial and potentially lasting impacts their entry may have on existing commercial brands. Offerings will also include historical data collected through Spherix's past research where applicable.

Methodology

Insights are based on data collected from an online survey of respondents recruited from the Spherix Network, a proprietary group of specialty physicians in clinical practice meeting quality screening criteria.

Sample Size & Frequency

- Quantitative: n=75 per specialty, per wave
- Reports in dermatology, gastroenterology, and rheumatology will be updated in Q2 and Q4 2022

Key Report Content*

- Patient volume (key indications)
- Aggregate analyses: geographic, demographic (including practice setting and structure, on-site services, patient age groups, payer mix)
- Biosimilar brand and manufacturer awareness
- Current attitudes on biosimilars
- General biosimilar awareness and FDA pathway familiarity
 - Comfort with label concepts
 - Comfort with required clinical data
 - Perceived cost savings
 - Greatest concerns with biosimilars
- Current market (where applicable)
 - Comfort with treatment scenarios
 - Current use
 - Prescription writing
 - Industry interactions
- Future market
 - Awareness/familiarity (therapy and manufacturer)
 - Anticipated use
 - Likelihood to prescribe
- Includes additional therapeutic area specific trended content

Key Service Features



Proprietary questions: Clients may submit two proprietary questions per wave, survey feedback encouraged



Presentation: On-site or virtual presentation with custom insights tailored towards your brand



Ad hoc analysis: Access to analytics and insights team, frequency tables and summary statistics available upon request



List match: Call list match with target group analysis provided at no charge



Publication embargo: Advanced report release for subscribed clients, three-day embargo on public dissemination

*see complete variable list for additional details